PHAT
Phathom Pharmaceuticals Inc
NASDAQ: PHAT · HEALTHCARE · BIOTECHNOLOGY
$11.20
-4.92% today
Updated 2026-04-30
Market cap
$935.69M
P/E ratio
—
P/S ratio
5.34x
EPS (TTM)
$-3.03
Dividend yield
—
52W range
$2 – $18
Volume
1.2M
Phathom Pharmaceuticals Inc (PHAT) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | $902000.00 | $257.18M | $295.11M | $189.43M | $164.81M | $413.84M | $378.32M |
| Cash & equivalents | $879000.00 | $243.76M | $287.50M | $183.26M | $155.38M | $381.39M | $297.26M |
| Current assets | $902000.00 | $255.60M | $291.37M | $186.53M | $160.51M | $397.43M | $360.13M |
| Total liabilities | $2.19M | $29.22M | $100.84M | $117.28M | $239.62M | $486.60M | $631.90M |
| Current liabilities | $2.19M | $3.75M | $55.52M | $18.92M | $26.24M | $38.78M | $85.73M |
| Long-term debt | — | $22.78M | $39.63M | $89.67M | $95.26M | $137.84M | $201.41M |
| Shareholder equity | $-1.29M | $227.96M | $194.27M | $72.16M | $-74.81M | $-72.76M | $-253.58M |
| Retained earnings | $-1.29M | $-256.42M | $-385.49M | $-529.37M | $-727.09M | $-928.68M | $-1.26B |
| Accounts receivable | — | — | $82000.00 | — | $0.00 | $1.64M | $38.80M |
| Inventory | — | — | $-82000.00 | — | $0.00 | $1.21M | $3.21M |
| Goodwill | — | — | — | — | — | — | — |